Anticardiolipin antibodies: isotype distribution and phospholipid specificity

Area of Science:

• Immunology
• Clinical Chemistry

Background:

• Antiphospholipid syndrome (APS) is characterized by the presence of antiphospholipid (aPL) antibodies and associated clinical complications.
• The role of specific immunoglobulin isotypes (IgG, IgM, IgA) and phospholipid specificities of anticardiolipin (aCL) antibodies in APS pathogenesis requires further elucidation.

Purpose of the Study:

• To determine the distribution of immunoglobulin isotypes and phospholipid specificities of aCL antibodies in patients with APS-associated clinical complications.
• To investigate potential associations between specific aCL antibody isotypes and clinical manifestations such as thrombosis, fetal loss, and thrombocytopenia.

Main Methods:

• Quantitative isotype-specific enzyme-linked immunosorbent assay (ELISA) was employed.
• The study analyzed 40 patients with one or more APS-associated clinical complications.
• Antibody binding to various phospholipids, including cardiolipin, phosphatidylserine, phosphatidylinositol, and phosphatidylcholine, was assessed.

Main Results:

• A significant proportion of patients (36/40) possessed IgG aCL antibodies, suggesting their potential importance.
• No statistical association was found between any single isotype or combination of isotypes (IgG, IgM, IgA) and the clinical complications.
• All tested immunoglobulin isotypes demonstrated binding to negatively charged phospholipids (phosphatidylserine, phosphatidylinositol) but not to zwitterionic phosphatidylcholine, indicating a broader specificity for negatively charged phospholipids rather than cardiolipin alone.

Conclusions:

• The study found no direct statistical link between specific immunoglobulin isotypes of aCL antibodies and APS-associated clinical complications.
• The findings suggest that aCL antibodies may target negatively charged phospholipids generally, rather than cardiolipin specifically.
• Further research is warranted to fully understand the complex interplay between aCL antibody isotypes, phospholipid specificity, and APS pathogenesis.